|
業務類別
|
Biotechnology |
|
業務概覽
|
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity. |
| 公司地址
| 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134 |
| 電話號碼
| +1 786 629-1376 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.relmada.com |
| 員工數量
| 17 |
| Mr. Charles S. Ence |
Chief Accounting and Compliance Officer |
美元 548.99K |
17/04/2026 |
| Mr. Paul Kelly |
Director and Chief Operating Officer |
美元 499.80K |
17/04/2026 |
| Mr. Maged Shenouda |
Chief Financial Officer |
美元 558.99K |
17/04/2026 |
| Dr. Sergio Traversa |
Chief Executive Officer and Director |
美元 787.79K |
17/04/2026 |
|
|
| Ms. Fabiana Fedeli |
Independent Director |
17/04/2026 |
| Mr. Paul Kelly |
Director and Chief Operating Officer |
17/04/2026 |
| Mr. John Glasspool |
Independent Director |
17/04/2026 |
| Dr. Sergio Traversa |
Chief Executive Officer and Director |
17/04/2026 |
| Mr. Charles J. Casamento |
Chairman of the Board |
17/04/2026 |
|
|
|
|
